Mineralys insider plans sale of 10,700 shares

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. insider Jon Congleton filed to sell common stock under Rule 144. The filing covers a proposed sale of 10,700 shares of common stock, to be executed through Merrill Lynch on 07/13/2026 on Nasdaq, with an aggregate market value of $291,441.17. These shares relate to restricted stock units that vested on 07/10/2026 and were granted under the issuer’s equity compensation plan. Over the prior three months, Congleton sold 15,730 shares for $421,979.55 on 04/13/2026 and 75,000 shares for $1,960,601.58 on 06/30/2026.

Filing Explained

The filing identifies 10,700 shares for sale after RSU vesting; it does not establish that those shares have been sold.

The July 13, 2026 Form 144 lists 10,700 Mineralys common shares for sale, with July 13, 2026 shown as the sale date.

The filing ties those shares to vesting of restricted stock unit awards granted under the issuer’s equity compensation plan and does not report that this listed sale has been completed.

Merrill Lynch is identified as the broker, and the filing states aggregate sale value of $291,441.17 against 82,498,101 shares outstanding.

Key Figures

Proposed shares to be sold: 10,700 shares Aggregate market value of proposed sale: $291,441.17 Shares previously sold on 04/13/2026: 15,730 shares +5 more

8 metrics

Proposed shares to be sold 10,700 shares Common stock to be sold through Merrill Lynch on 07/13/2026

Aggregate market value of proposed sale $291,441.17 Value of 10,700 shares of common stock in the planned Rule 144 sale

Shares previously sold on 04/13/2026 15,730 shares Common stock sold by Jon Congleton during past 3 months

Proceeds from 04/13/2026 sale $421,979.55 Aggregate sale price for 15,730 shares on 04/13/2026

Shares previously sold on 06/30/2026 75,000 shares Common stock sold by Jon Congleton during past 3 months

Proceeds from 06/30/2026 sale $1,960,601.58 Aggregate sale price for 75,000 shares on 06/30/2026

RSU vesting date 07/10/2026 Date Restricted Stock Unit Awards vested related to the 10,700 shares

Planned sale date 07/13/2026 Proposed date of Rule 144 sale of 10,700 shares on Nasdaq

Key Terms

Form 144, Restricted Stock Unit Awards, equity compensation plan, aggregate market value

4 terms

Form 144 regulatory

"Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Unit Awards financial

"Common Stock | 07/10/2026 | Vesting of Restricted Stock Unit Awards"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

aggregate market value financial

"Common Stock | Merrill Lynch ... | 10700 | 291441.17"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does Mineralys Therapeutics (MLYS) Form 144 disclose about planned share sales?

The Form 144 discloses that 10,700 shares of Mineralys Therapeutics common stock may be sold on 07/13/2026 through Merrill Lynch on Nasdaq, with an aggregate market value of $291,441.17 based on the filing information.

Who is the reporting person in the Mineralys Therapeutics (MLYS) Form 144 filing?

The reporting person is Jon Congleton. The filing covers his potential sale of 10,700 shares of Mineralys Therapeutics common stock under Rule 144, along with disclosure of his prior sales over the last three months.

How many Mineralys Therapeutics (MLYS) shares did Jon Congleton sell in the past three months?

Jon Congleton sold 15,730 shares on 04/13/2026 for $421,979.55 and 75,000 shares on 06/30/2026 for $1,960,601.58, as reported in the three‑month sale history accompanying the Form 144 filing.

What is the origin of the 10,700 Mineralys Therapeutics (MLYS) shares in this Form 144?

The 10,700 shares proposed for sale are tied to the vesting of Restricted Stock Unit Awards on 07/10/2026, which were originally granted as part of the issuer’s equity compensation plan for Jon Congleton.

On which market and through which broker will the Mineralys Therapeutics (MLYS) shares be sold?

The Form 144 states that the 10,700 shares of Mineralys Therapeutics common stock are expected to be sold on Nasdaq through Merrill Lynch, located at 225 Liberty St, 37th Floor, New York, NY 10281.

What security is covered by the Mineralys Therapeutics (MLYS) Form 144 filing?

The filing covers Common Stock of Mineralys Therapeutics, Inc., identified with CUSIP 82498101. It details a planned Rule 144 sale of 10,700 shares plus prior common stock sales over the preceding three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 04:23 PM Accepted by SEC EDGAR 07/13/2026 - 04:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001644975
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Congleton Jon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St 37th Floor New York NY 10281	10700	291441.17	82498101	07/13/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/10/2026	Vesting of Restricted Stock Unit Awards	Mineralys Therapeutics, Inc.			10700	07/10/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	04/13/2026	15730	421979.55
Jon Congleton 150 N. RADNOR CHESTER RD SUITE F200 RADNOR PA 19087	Common Stock	06/30/2026	75000	1960601.58

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jon Congleton
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)